Request Deal Involvement
Karo Pharma to acquire Sylphar from Vendis Capital for $326m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
White & Case
financial advisors
Rothschild & Co
or
Principals
bidder
KARO PHARMA AB
vendor
ROBIN LIST
target
SYLPHAR
vendor
VENDIS CAPITAL MANAGEMENT
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite